Accrued expenses on funding commitment related to clinical research.

No definition available.

Name:	biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch
Namespace Prefix:	biib_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Cumulative sales level

+ References

No definition available.

+ Details

Name:	biib_CumulativeSalesLevel
Namespace Prefix:	biib_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Future contingent payment for annual worldwide net sales that exceed $2.0 billion

+ References

No definition available.

+ Details

Name:	biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion
Namespace Prefix:	biib_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Future contingent payment for annual worldwide net sales up to $2.0 billion

+ References

No definition available.

+ Details

Name:	biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion
Namespace Prefix:	biib_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Future contingent payment threshold

+ References

No definition available.

+ Details

Name:	biib_FutureContingentPaymentThreshold
Namespace Prefix:	biib_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Percentage of royalties as per collaboration.

+ References

No definition available.

+ Details

Name:	biib_PercentageOfRoyaltiesAsPerCollaboration
Namespace Prefix:	biib_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Potential future milestone payments commitment to third party approximately.

+ References

No definition available.

+ Details

Name:	biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
Namespace Prefix:	biib_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Royalties Payable Period, Post FDA Approval

+ References

No definition available.

+ Details

Name:	biib_RoyaltiesPayablePeriodPostFDAApproval
Namespace Prefix:	biib_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_BusinessAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319

+ Details

Name:	us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585

+ Details

Name:	us-gaap_IncomeTaxesPaid
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount recognized for uncertainty in income taxes classified as current.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_LiabilityForUncertainTaxPositionsCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.

+ References

No definition available.

+ Details

Name:	us-gaap_OtherCommitment
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585

+ Details

Name:	us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_IncomeTaxAuthorityAxis=biib_U.S.2017TaxActMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	biib_FutureContingentMilestoneTypesAxis=biib_DevelopmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ConsolidatedEntitiesAxis=biib_NeurimmuneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	biib_FutureContingentMilestoneTypesAxis=biib_CommercialMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=biib_SPINRAZAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=biib_AlkermesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=biib_VUMERITYMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=biib_AducanumabMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=biib_EisaiMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=biib_ADUHELMMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	biib_ExpectedPaymentTimelineofMilestoneAxis=biib_TwelvemonthsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=us-gaap_EuropeanUnionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=country_JP
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=biib_TysabriProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=biib_FumarateMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	biib_CumulativeSalesLevelAxis=biib_TwentybillionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	biib_CumulativeSalesLevelAxis=biib_EachAdditionalOneBillionUpToTwentyBillionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and Contingencies (Details) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
Commitments and Contingencies (Details) - USD ($)	Oct. 31, 2019	Mar. 31, 2019	Dec. 31, 2021	Dec. 31, 2016	Dec. 31, 2022	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2013
Business Acquisition [Line Items]
Contingent payment		$ 300,000,000
Potential future milestone payments commitment, approximately			$ 10,000,000,000
Accrued expenses			27,300,000
Cancellable future commitments			676,100,000
Liabilities associated with uncertain tax positions			106,800,000
Income taxes paid			72,700,000
2017 Tax Act
Business Acquisition [Line Items]
Transition toll tax liabilities			633,000,000				$ 697,000,000
Development Milestones
Business Acquisition [Line Items]
Potential future milestone payments commitment, approximately			2,000,000,000
Regulatory Milestones
Business Acquisition [Line Items]
Potential future milestone payments commitment, approximately			900,000,000
Regulatory Milestones \| Neurimmune
Business Acquisition [Line Items]
Potential future milestone payments commitment, approximately								$ 75,000,000
Commercial Milestones
Business Acquisition [Line Items]
Potential future milestone payments commitment, approximately			$ 7,100,000,000
Ionis Pharmaceuticals \| Minimum \| SPINRAZA
Business Acquisition [Line Items]
Percentage of royalties as per collaboration			11.00%	11.00%
Ionis Pharmaceuticals \| Maximum \| SPINRAZA
Business Acquisition [Line Items]
Percentage of royalties as per collaboration			15.00%	15.00%
Alkermes
Business Acquisition [Line Items]
Potential future milestone payments commitment, approximately									$ 155,000,000
Alkermes \| VUMERITY
Business Acquisition [Line Items]
Percentage of royalties as per collaboration	15.00%		15.00%
Royalties payable period, post FDA approval	5 years
Aducanumab \| Forecast
Business Acquisition [Line Items]
Potential future milestone payments commitment, approximately					$ 133,900,000
Eisai \| ADUHELM \| Twelve months
Business Acquisition [Line Items]
Potential future milestone payments commitment, approximately			$ 100,000,000
Eisai \| ADUHELM \| Regulatory Milestones \| Neurimmune
Business Acquisition [Line Items]
Potential future milestone payments commitment, approximately						$ 100,000,000
Eisai \| ADUHELM \| Regulatory Milestones \| European Union
Business Acquisition [Line Items]
Potential future milestone payments commitment, approximately			50,000,000
Eisai \| ADUHELM \| Regulatory Milestones \| JAPAN
Business Acquisition [Line Items]
Potential future milestone payments commitment, approximately			50,000,000
TYSABRI
Business Acquisition [Line Items]
Future contingent payment for annual worldwide net sales up to threshold, percentage											18.00%
Future contingent payment threshold											$ 2,000,000,000
Future contingent payment for annual worldwide net sales that exceeding threshold, percentage											25.00%
Fumapharm AG \| Fumarate \| Twenty billion
Business Acquisition [Line Items]
Cumulative sales level									$ 20,000,000,000
Fumapharm AG \| Fumarate \| Each additional one billion up to twenty billion
Business Acquisition [Line Items]
Cumulative sales level			20,000,000,000							$ 20,000,000,000
Convergence Pharmaceuticals
Business Acquisition [Line Items]
Maximum contingent consideration in the form of development and approval milestones			$ 400,000,000